Coloplast's important growth market still curbed by the pandemic
China is a key part of the medtech company’s growth plan for its ostomy business, but extensive Covid-19 restrictions are hampering growth. ”We don’t predict any improvements this calendar year,” says CFO Anders Lonning-Skovgaard.
by ulrich quistgaard, translated by daniel pedersen
Although Coloplast has geared back up after the pandemic, reporting 8% organic growth and an operating margin of 30% before special items in the latest quarter, one thing in particular is slowing the medtech company down.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast has inflation concerns
For subscribers
Coloplast presents strong Q3 figures
For subscribers
Coloplast is phasing out natural gas
For subscribers
